NL-OMON40805已完成不适用
Randomized, double-blind, placebo-controlled, three way crossover, double dummy, single centre study evaluating the effect of haloperidol 2 mg and lorazepam 1 mg on posturography and underlying systems involved in standing balance in 12 healthy elderly subjects. - BalRoom study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Healthy male and/or female subjects of non-childbearing potential over the age of 70 years (inclusive; healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12-lead ECG, and clinical laboratory tests).;2. Body Mass Index (BMI) of 17.5 to 35 kg/m2; and a total body weight =>50 kg.;3. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.;4. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures. ;5. Mini-Mental State Examination (MMSE) score > 26 points at screening.
排除标准
- •1. Evidence or history of clinically significant haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).;2. Subjects presenting with orthostatic hypotension, in which orthostatic hypotension is defined as a decrease of 20 mmHg for systolic blood pressure or 10 mmHg for diastolic blood pressure 2 minutes after standing from a supine position.;3. Any condition possibly affecting drug absorption (eg, gastrectomy).;4. A positive urine drug screen.;5. History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males (1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor) within 6 months of Screening.;6. Treatment with an investigational drug within 3 months prior to screening or having participated in more than 4 investigational drug studies within 1 year prior to screening.;7. Use of (non- )prescription medications that are believed to affect subject safety or the overall results of the study following judgment by the investigator.;8. Loss or donation of blood over 500 mL within three months (males) or four months (females) prior to screening;9. Unwilling or unable to comply with the Lifestyle Guidelines described in this protocol.;10. Physically unable to perform BalRoom tests, e.g. walking and standing tests.;11. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.;12. Subjects who are investigational site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the Investigator, or subjects directly involved in the conduct of the study.;13. Clinical significant abnormalities on ECG and or QTcF > 500ms.
研究者
相似试验
尚未招募
不适用
ESMAVAC - 1MalariaPACTR201712002879427Centre de Recherches Médicale de Lambaréné
进行中（未招募）
1 期
A comparison study of TRx0237 (LMTM) and placebo in patients with Alzheimer's Disease.EUCTR2017-003558-17-PLTauRx Therapeutics Ltd450
进行中（未招募）
1 期
A comparison study of TRx0237 (LMTM) and placebo in patients with early Alzheimer's Disease.EUCTR2017-003558-17-ESTauRx Therapeutics Ltd375
进行中（未招募）
1 期
A comparison study of TRx0237 (LMTM) and placebo in patients with early Alzheimer's Disease.Alzheimer’s DiseaseMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2017-003558-17-ITTAURX THERAPEUTICS LTD375
进行中（未招募）
1 期
A comparison study of TRx0237 (LMTM) and placebo in patients with Alzheimer's Disease.Alzheimer’s DiseaseMedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2017-003558-17-BETauRx Therapeutics Ltd450